Saffron effect in Chronic Obstructive Pulmonary Disease (COPD).

The effect of saffron on pulmonary function and serum levels of Interleukin-6 and Tumor Necrosis Factor-a in patients with Chronic Obstructive Pulmonary Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110109005579N2

Enrollment

Registered

2019-09-17

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. Other specified Chronic Obstructive Pulmonary Disease

Interventions

Intervention 1: "Intervention group:" Patients with Chronic Obstructive Pulmonary Disease will be receive standard treatments based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gui

Eligibility

Sex/Gender

Male

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Chronic Obstructive Pulmonary Disease Age between 40-85 Clinically stable disease in previous 8 weeks Acceptance of study design by patients

Exclusion criteria

Exclusion criteria: Active infectious disease Bronchiectasis Chronic inflammatory diseases Active liver and kidney diseases Cancer patients Cardiac disease (myocardial infarction and unstable angina in previous 6 months) Sensitivity to saffron

Design outcomes

Primary

Measure	Time frame
Serum Level of IL-6. Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Tumor Necrosis factor alpha (TNF-a). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Pulmonary Function Test. Timepoint: beginning of study and 12 weeks after intervention. Method of measurement: Laboratory (Spirometry Device).;Total oxidant status (TOS). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Total antioxidant capacity (TAC). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Nuclear factor kappa B (NF-?B). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.	—

Measure

Time frame

Serum Level of IL-6. Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Tumor Necrosis factor alpha (TNF-a). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Pulmonary Function Test. Timepoint: beginning of study and 12 weeks after intervention. Method of measurement: Laboratory (Spirometry Device).;Total oxidant status (TOS). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Total antioxidant capacity (TAC). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.;Nuclear factor kappa B (NF-?B). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Laboratory.

—

Secondary

Measure	Time frame
COPD Assessment Test (CAT). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: CAT Questionnaire, accessible at: https://www.catestonline.org.;Dyspnea scale: Modified Medical Research Council (MMRC) questionnaire. Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Modified Medical Research Council (MMRC) questionnaire.;Exercise scale: Six Minute Walk Distance (6MWD). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Six Minute Walk Distance (6MWD) questionnaire.;Oxygen saturation of arterial blood. Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Pulse oximetry.;Saffron side effects. Timepoint: 4 weeks and 12 weeks after intervention. Method of measurement: Record of adverse effect in checklist.	—

Measure

Time frame

COPD Assessment Test (CAT). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: CAT Questionnaire, accessible at: https://www.catestonline.org.;Dyspnea scale: Modified Medical Research Council (MMRC) questionnaire. Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Modified Medical Research Council (MMRC) questionnaire.;Exercise scale: Six Minute Walk Distance (6MWD). Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Six Minute Walk Distance (6MWD) questionnaire.;Oxygen saturation of arterial blood. Timepoint: Beginning of study and 12 weeks after intervention. Method of measurement: Pulse oximetry.;Saffron side effects. Timepoint: 4 weeks and 12 weeks after intervention. Method of measurement: Record of adverse effect in checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Ghobadi

Ardabil University of Medical Sciences

h.ghobadi@arums.ac.ir009833251410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026